Edwards Lifesciences Co. (NYSE:EW) Shares Sold by CANADA LIFE ASSURANCE Co

CANADA LIFE ASSURANCE Co cut its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.4% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 634,942 shares of the medical research company’s stock after selling 9,136 shares during the period. CANADA LIFE ASSURANCE Co owned about 0.11% of Edwards Lifesciences worth $60,742,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Martin Capital Advisors LLP raised its position in shares of Edwards Lifesciences by 0.5% during the 4th quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock worth $1,944,000 after purchasing an additional 128 shares during the last quarter. Chapin Davis Inc. lifted its position in shares of Edwards Lifesciences by 1.7% in the first quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock valued at $817,000 after acquiring an additional 140 shares in the last quarter. Johnson Financial Group Inc. boosted its stake in shares of Edwards Lifesciences by 23.0% in the fourth quarter. Johnson Financial Group Inc. now owns 771 shares of the medical research company’s stock worth $59,000 after acquiring an additional 144 shares during the last quarter. Valley National Advisers Inc. increased its position in shares of Edwards Lifesciences by 6.0% during the first quarter. Valley National Advisers Inc. now owns 2,677 shares of the medical research company’s stock worth $255,000 after purchasing an additional 152 shares in the last quarter. Finally, Choreo LLC raised its stake in Edwards Lifesciences by 4.1% in the 1st quarter. Choreo LLC now owns 3,840 shares of the medical research company’s stock valued at $367,000 after purchasing an additional 153 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Wells Fargo & Company upped their target price on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the stock an “overweight” rating in a report on Friday, April 26th. Evercore ISI raised their target price on shares of Edwards Lifesciences from $89.00 to $91.00 and gave the stock an “in-line” rating in a research note on Tuesday, July 2nd. Piper Sandler upped their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a research report on Friday, April 26th. Mizuho lifted their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Finally, Royal Bank of Canada boosted their price objective on Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research note on Monday, April 15th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $96.13.

Insiders Place Their Bets

In other Edwards Lifesciences news, CEO Bernard J. Zovighian acquired 580 shares of the stock in a transaction dated Monday, May 6th. The stock was acquired at an average price of $85.74 per share, with a total value of $49,729.20. Following the completion of the purchase, the chief executive officer now owns 3,268 shares in the company, valued at approximately $280,198.32. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total transaction of $466,450.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $4,378,659.44. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Bernard J. Zovighian purchased 580 shares of Edwards Lifesciences stock in a transaction on Monday, May 6th. The stock was bought at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the transaction, the chief executive officer now directly owns 3,268 shares in the company, valued at $280,198.32. The disclosure for this purchase can be found here. Insiders have sold 81,099 shares of company stock worth $7,003,553 over the last three months. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Down 0.1 %

Shares of NYSE:EW traded down $0.10 during mid-day trading on Wednesday, reaching $86.95. 3,277,317 shares of the company were exchanged, compared to its average volume of 3,397,984. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. The firm’s 50-day simple moving average is $89.12 and its 200 day simple moving average is $87.12. The firm has a market cap of $52.40 billion, a price-to-earnings ratio of 37.48, a P/E/G ratio of 3.22 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. The business had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.65 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The company’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period last year, the business posted $0.66 earnings per share. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.